Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-977-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.84 million
Profitability
Miscellaneous
Employees373
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) posted its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.94) by $0.02. The biopharmaceutical company earned $21.90 million during the quarter, compared to analyst estimates of $19.61 million. View Insmed's Earnings History.
When is Insmed's next earnings date?
What price target have analysts set for INSM?
7 brokers have issued 1-year price targets for Insmed's stock. Their predictions range from $22.00 to $52.00. On average, they anticipate Insmed's share price to reach $38.2857 in the next twelve months. This suggests a possible upside of 45.4% from the stock's current price. View Analyst Price Targets for Insmed.
What is the consensus analysts' recommendation for Insmed?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.
What are Wall Street analysts saying about Insmed stock?
Here are some recent quotes from research analysts about Insmed stock:
- 1. According to Zacks Investment Research, "Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. " (5/11/2019)
- 2. HC Wainwright analysts commented, "Our price target of $52/share is based on: (a) $51/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.58 discounted back to and (b) an NPV of $52/share, (discount rate 12.0%, growth rate 2%), with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors." (4/9/2019)
Has Insmed been receiving favorable news coverage?
News articles about INSM stock have been trending positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insmed earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY), Beigene (BGNE), Nektar Therapeutics (NKTR), Amarin (AMRN), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Insmed own?
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
- Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
- Mr. Roger Adsett, Chief Commercial Officer (Age 50)
- Dr. Paul D. Streck, Advisor (Age 55)
Who are Insmed's major shareholders?
Insmed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.98%), Vivo Capital LLC (1.51%), Geode Capital Management LLC (1.23%), Northern Trust Corp (1.22%), Emerald Advisers LLC (1.19%) and Emerald Mutual Fund Advisers Trust (1.08%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.
Which institutional investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Voya Investment Management LLC, Asymmetry Capital Management L.P., Man Group plc, Dimensional Fund Advisors LP, TD Asset Management Inc., SG Americas Securities LLC and Parametric Portfolio Associates LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which institutional investors are buying Insmed stock?
INSM stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Federated Investors Inc. PA, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Geode Capital Management LLC, Rice Hall James & Associates LLC, FMR LLC and Principal Financial Group Inc.. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari, Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $26.33.
How big of a company is Insmed?
Insmed has a market capitalization of $2.04 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.
What is Insmed's official website?
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
